Promoter holding
64.27%
ID
Igenetic Diagnostics Private Limited - Due diligence report
A 360° intelligence report on Igenetic Diagnostics: trust score, financial health, credit view, compliance, directors, growth and distress s…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Igenetic Diagnostics — 360° Intelligence Report
Generated from MCA filings & public records63/100
Trust Score
Moderate
Igenetic Diagnostics is assessed as Moderate with a Trust Score of 63/100. Igenetic Diagnostics is an active private limited indian non-government company incorporated in 2013, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Igenetic Diagnostics Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
63/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
68/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
25/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
50/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
- Elevated gearing (D/E 38%).
- Externally credit-rated (BB+).
Charges position: 0 open (-) · 4 satisfied (9.25 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Yes Bank Limited | 1 | 48.0 cr |
| Siemens Financial Services Private Limited | 2 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
Compliance Score: 68/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
- 1 auditor resignation(s) filed - latest: HAREN SANGHVI & ASSOCIATES on 2019-09-26.
- Delayed payments to MSME suppliers disclosed (137 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ARUNIMA PATEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMOJI TEJOMURTULA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NAGENDRA SWAMY SRIRANGAPATNA CHANDRASHEKHARAIAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARINARAYAN SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 4 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
17 allotment(s) · 6 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 70 · Distress 50
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Operating for 12+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Outside liabilities up 2.1x in a year.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 45.18 Lakh.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence61/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 3 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment42/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view52/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events22 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
31 Mar 2023
Share transfer (FY 2023)
1613.00000000 shares to Sandeep Sharma
05 Mar 2022
Securities allotted
35166 Equity Shares - 6.15 cr raised
07 Jan 2022
Securities allotted
112 Equity Shares - 10.00 Lakh raised
14 Oct 2021
Director ceased
MADHUSUDAN SHARMA
06 Aug 2021
Securities allotted
9574 Equity Shares - 8,929.00 raised
Securities allotted
52210 Equity Shares - 100.00 raised
05 Aug 2021
Director ceased
HOMER SWARAJ PANERI
12 Feb 2020
Securities allotted
5995187 Debentures - 59.95 Lakh raised
23 Jan 2020
Securities allotted
80498230 Debentures - 8.05 cr raised
09 Oct 2019
Charge satisfied
Yes Bank Limited
24 Jul 2019
Charge satisfied
Siemens Financial Services Private Limited
07 May 2019
Charge satisfied
Siemens Financial Services Private Limited
17 Jul 2018
Securities allotted
26155 Preference Shares - 30.00 cr raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 4 registered charge(s) stand satisfied - past borrowings repaid.
Carries an external credit rating of BB+ from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 17 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Avishkar International Private Limited | U51507MH2004PTC144316 | Mumbai, Maharashtra, India |
| Triomics | U85300UP2020PTC136648 | Surajpur, Uttar Pradesh, India |
| Progenesis Ivf Private Limited | U85320MH2019PTC330820 | Thane, Maharashtra, India |
| Polo Labs | U70200CH1998PTC021322 | Chandigarh, Chandigarh, India |
| Blisson Mediplus Private Limited | U11100MH2013PTC244233 | Mumbai, Maharashtra, India |
| Sakhiyaskinclinic | U85110GJ2011PLC121885 | Surat City, Gujarat, India |
| Gemini Scans Private Limited | U33125TN2006PTC061121 | Chennai, Tamil Nadu, India |
| Mp Biomedicals India Private Limited | U24100MH2009PTC191394 | Navi Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Igenetic Diagnostics before audits and certifications: compliance score 68/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Igenetic Diagnostics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Enhanced diligence advised. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Igenetic Diagnostics - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 63/100, distress signals and MSME payment-delay disclosures - know whether Igenetic Diagnostics pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Igenetic Diagnostics - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Igenetic Diagnostics an active company?
Igenetic Diagnostics has MCA status “Active” with a compliance score of 68/100 (Moderate).
Is Igenetic Diagnostics financially healthy?
Igenetic Diagnostics has a Financial Health Score of 25/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Igenetic Diagnostics?
Its overall Trust Score is 63/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Igenetic Diagnostics?
Promoters hold a majority stake - exact percentages are in the full report. 4 active director(s) are on record.
Does Igenetic Diagnostics have loans or charges against its assets?
No open charges - all 4 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Igenetic Diagnostics up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 68/100 (Moderate).
Is it risky to lend to Igenetic Diagnostics?
Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
